Organ transplant recipients have a 200-fold increased incidence of keratinocyte carcinoma compared with immunocompetent individuals, and cSCC accounts for 80% of skin cancers in those recipients.
Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department of Population Health, University of Oxford.